{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:44Z","timestamp":1787009924108,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/cco.0b013e328324bc04","type":"journal-article","created":{"date-parts":[[2009,2,19]],"date-time":"2009-02-19T06:31:52Z","timestamp":1235025112000},"page":"162-170","source":"Crossref","is-referenced-by-count":19,"title":["Stem cell transplantation for multiple myeloma"],"prefix":"10.1097","volume":"21","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood.V110.11.74.74","article-title":"A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [ASH Annual Meeting Abstracts]","volume":"110","author":"Rajkumar","year":"2007","journal-title":"Blood"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":"Comparison of 200 mg\/m2 melphalan and 8 Gy total body irradiation plus 140 mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My\u00e9lome 9502 randomized trial","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","article-title":"Age is not a prognostic variable with autotransplants for multiple myeloma","volume":"93","author":"Siegel","year":"1999","journal-title":"Blood"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1705627","article-title":"Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma","volume":"39","author":"Gertz","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1704545","article-title":"High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/bmt.2008.24","article-title":"Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT","volume":"41","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02785870","article-title":"Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment","volume":"16","author":"Knudsen","year":"1999","journal-title":"Med Oncol"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","article-title":"Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone","volume":"20","author":"Alegre","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and \u221217p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis","volume":"21","author":"Gutierrez","year":"2007","journal-title":"Leukemia"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bmt.1705307","article-title":"Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients","volume":"37","author":"O'Shea","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1702640","article-title":"Effect of complete response on outcome following autologous stem cell transplantation for myeloma","volume":"26","author":"Rajkumar","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.bmt.1701787","article-title":"Beta 2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma","volume":"23","author":"Rajkumar","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood.V106.11.2545.2545","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial [ASH Annual Meeting Abstracts]","volume":"106","author":"Sonneveld","year":"2005","journal-title":"Blood"},{"issue":"Suppl 1","key":"R32-13-20210128","first-page":"S59","article-title":"Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM)","volume":"4","author":"Fermand","year":"2003","journal-title":"Hematol J"},{"key":"R33-13-20210128","first-page":"7","article-title":"Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy","volume":"16","author":"Tricot","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajh.20641","article-title":"Prolonged overall survival with second on-demand autologous transplant in multiple myeloma","volume":"81","author":"Elice","year":"2006","journal-title":"Am J Hematol"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.2004.06.144","article-title":"Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study","volume":"22","author":"Morris","year":"2004","journal-title":"J Clin Oncol"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","article-title":"Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial","volume":"111","author":"Abdelkefi","year":"2008","journal-title":"Blood"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V108.11.798.798","article-title":"Lenalidomide plus dexamethasone (rev\/dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival [abstract]","volume":"108","author":"Lacy","year":"2006","journal-title":"Blood"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood.V110.11.77.77","article-title":"Superiority of lenalidomide (len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [ASH Annual Meeting Abstracts]","volume":"110","author":"Zonder","year":"2007","journal-title":"Blood"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"A333","DOI":"10.1182\/blood.V104.11.333.333","article-title":"A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma [abstract]","volume":"104","author":"Jagannath","year":"2004","journal-title":"Blood"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V110.11.450.450","article-title":"VELCADE\/Dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 trial [ASH Annual Meeting Abstracts]","volume":"110","author":"Harousseau","year":"2007","journal-title":"Blood"},{"key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.V104.11.929.929","article-title":"Addition of bortezomib (VelcadeTM) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM) [ASH Annual Meeting Abstracts]","volume":"104","author":"Hollmig","year":"2004","journal-title":"Blood"},{"key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1158\/1078-0432.CCR-04-1106","article-title":"Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant","volume":"10","author":"Stewart","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R45-13-20210128","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705339","article-title":"Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma","volume":"37","author":"Sahebi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R46-13-20210128","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bmt.1704968","article-title":"Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma","volume":"35","author":"Arora","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R49-13-20210128","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"key":"R50-13-20210128","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bmt.1704289","article-title":"Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect","volume":"32","author":"Alyea","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R51-13-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2007.04.006","article-title":"Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma","volume":"13","author":"Kuruvilla","year":"2007","journal-title":"Biology of blood and marrow transplantation"},{"key":"R52-13-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u20138 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"R53-13-20210128","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"R54-13-20210128","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"R55-13-20210128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"R56-13-20210128","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"R57-13-20210128","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e328324bc04","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:08:27Z","timestamp":1620936507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-200903000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e328324bc04","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}